Aclaris priced 7,785,714 shares at $3.50 and pre-funded warrants for 6,500,000 more shares, $49,999,934 before costs, on the day it announced small Phase 1b results for its antibody ATI-052. The prospectus puts cash at approximately $204.6 million on September 30, 2026.
Aclaris also pointed to a private placement financing announced the same morning and said it maintains its cash runway into 2028. The release gives no license payment terms.
Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $19.2 million, plus short-term investments of $72.4 million, $91.6 million in all.
Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.
Questions about Aclaris Therapeutics
Has Aclaris Therapeutics raised money recently?
Our latest story on this, dated Oct 27, 2026: "Aclaris Therapeutics prices $49,999,934 stock and pre-funded warrant offering". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of Aclaris Therapeutics?
Aclaris Therapeutics, Inc. trades under the ticker ACRS on NASDAQ.
Where is Aclaris Therapeutics listed?
Aclaris Therapeutics, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:8AT; LSE:0H8T; LSX:A1412H.
What is the SEC CIK of Aclaris Therapeutics?
The SEC Central Index Key (CIK) for Aclaris Therapeutics, Inc. is 1557746. Its filings are on SEC EDGAR.
How many shares does Aclaris Therapeutics have outstanding?
147,198,893 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-06.
Which country or territory is Aclaris Therapeutics listed under?
Our directory records Aclaris Therapeutics, Inc. under United States.
What does Aclaris Therapeutics do?
Our directory classifies Aclaris Therapeutics, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
What is the ISIN of Aclaris Therapeutics?
The ISIN recorded for Aclaris Therapeutics, Inc. is US00461U1051.
Does aibio.space cover Aclaris Therapeutics?
aibio.space lists Aclaris Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Aclaris Therapeutics incorporated?
SEC records list its state or country of incorporation as DE.
Is Aclaris Therapeutics profitable?
Aclaris Therapeutics, Inc. reported a net loss of $64.9 million for the fiscal year ended Dec 31, 2025, and used $47.1 million of cash in operations, per its annual report to the SEC.
How much does Aclaris Therapeutics spend on research and development?
$52.6 million in the fiscal year ended Dec 31, 2025, per its annual report.
How much cash does Aclaris Therapeutics have?
$91.6 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.
What is the latest Aclaris Therapeutics (ACRS) stock news?
Our latest story on Aclaris Therapeutics, dated Oct 27, 2026: "Aclaris Therapeutics prices $49,999,934 stock and pre-funded warrant offering". Aclaris priced 7,785,714 shares at $3.50 and pre-funded warrants for 6,500,000 more shares, $49,999,934 before costs, on the day it announced small Phase 1b results for its antibody ATI-052. The prospectus puts cash at approximately $204.6 million on September 30, 2026. Source.
How long will Aclaris Therapeutics's cash last?
From our story of Nov 18, 2024: Aclaris also pointed to a private placement financing announced the same morning and said it maintains its cash runway into 2028. Source.
Investor discussion: Aclaris Therapeutics
Members talk about Aclaris Therapeutics (ACRS). Reader posts, not aibio.space reporting, and not investment advice.
Rules
Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.
Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.
Capital-markets timeline
Financings, listing notices, splits, legal actions and other investor events at Aclaris Therapeutics, newest first. Each line links the filing it comes from.
Reported a financing. SEC Form 8-K (Items 7.01). Source
Financings
Reported a financing. SEC Form 8-K (Items 1.01,3.02,5.02,7.01,8.01,9.01). Source
Stock chart
Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NASDAQ:ACRS on TradingView.
SEC filings and registration
SEC name
Aclaris Therapeutics, Inc.
CIK
1557746
Industry (SIC)
Pharmaceutical Preparations (2834)
US tickers
ACRS (Nasdaq)
State or country of incorporation
DE
Fiscal year ends
December 31
Filer category
Non-accelerated filer<br>Smaller reporting company
Business address
701 LEE ROAD, WAYNE, PA, 19087
Phone
484-324-7933
Shares outstanding
147,198,893 as of 2026-07-31 (10-Q filed 2026-08-06)
Recent filings (8-K and 6-K are the company's own announcements)
Source: SEC EDGAR, retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.
Listing details
Aclaris Therapeutics, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker ACRS, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.
Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.
Published and maintained by aibio.space. Not investment advice. How we work.
Who manages this pageThis page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio